C4 Therapeutics Inc
CCCC2.140USD
-0.050-2.28%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
158.73MMarket Cap
LossP/E TTM
More Details of C4 Therapeutics Inc Company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
C4 Therapeutics Inc Info
Ticker SymbolCCCC
Company nameC4 Therapeutics Inc
IPO dateOct 02, 2020
CEOHirsch (Andrew J)
Number of employees110
Security typeOrdinary Share
Fiscal year-endOct 02
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16172310700
Websitehttps://c4therapeutics.com/
Ticker SymbolCCCC
IPO dateOct 02, 2020
CEOHirsch (Andrew J)
Company Executives of C4 Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
168.59K
+3475.00%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
118.56K
+13556.00%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+51238.00%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Kenneth C. (Ken) Anderson, M.D.
Dr. Kenneth C. (Ken) Anderson, M.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Ms. Kelly A. Schick
Ms. Kelly A. Schick
Chief People Officer
Chief People Officer
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
168.59K
+3475.00%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
118.56K
+13556.00%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+51238.00%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Kenneth C. (Ken) Anderson, M.D.
Dr. Kenneth C. (Ken) Anderson, M.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.75%
RA Capital Management, LP
8.25%
Lynx1 Capital Advisors LLC
7.32%
Soleus Capital Management, L.P.
7.28%
OrbiMed Advisors, LLC
5.40%
Other
62.99%
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.75%
RA Capital Management, LP
8.25%
Lynx1 Capital Advisors LLC
7.32%
Soleus Capital Management, L.P.
7.28%
OrbiMed Advisors, LLC
5.40%
Other
62.99%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.96%
Investment Advisor
17.54%
Venture Capital
8.41%
Investment Advisor/Hedge Fund
8.15%
Research Firm
7.96%
Private Equity
5.40%
Corporation
5.03%
Individual Investor
2.44%
Pension Fund
0.09%
Other
20.01%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
295
70.29M
72.52%
+1.58M
2025Q3
308
52.96M
108.83%
-2.15M
2025Q2
306
55.08M
118.23%
-10.19M
2025Q1
320
64.50M
110.39%
-13.86M
2024Q4
320
64.84M
109.43%
+173.51K
2024Q3
315
64.67M
104.71%
+3.40M
2024Q2
309
61.26M
103.56%
+2.76M
2024Q1
313
58.50M
89.36%
-2.80M
2023Q4
309
47.27M
101.07%
+10.16M
2023Q3
305
34.95M
100.17%
+181.16K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Point72 Asset Management, L.P.
8.48M
8.75%
+8.48M
--
Oct 17, 2025
RA Capital Management, LP
8.00M
8.25%
+8.00M
--
Oct 17, 2025
Lynx1 Capital Advisors LLC
7.10M
7.32%
--
--
Sep 30, 2025
Soleus Capital Management, L.P.
7.05M
7.28%
+75.00K
+1.07%
Sep 30, 2025
OrbiMed Advisors, LLC
5.24M
5.4%
-1.60M
-23.35%
Sep 30, 2025
Betta investment Hong Kong Ltd
4.87M
5.03%
-693.38K
-12.45%
Apr 22, 2025
Morgan Stanley & Co. LLC
4.86M
5.02%
+1.71M
+54.22%
Sep 30, 2025
Wasatch Global Investors Inc
4.85M
5.01%
-2.57M
-34.64%
Sep 30, 2025
The Vanguard Group, Inc.
3.19M
3.29%
+173.53K
+5.75%
Sep 30, 2025
BofA Global Research (US)
2.05M
2.12%
+45.16K
+2.25%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Fidelity Enhanced Small Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of C4 Therapeutics Inc?
The top five shareholders of C4 Therapeutics Inc are:
Point72 Asset Management, L.P. holds 8.48M shares, accounting for 8.75% of the total shares.
RA Capital Management, LP holds 8.00M shares, accounting for 8.25% of the total shares.
Lynx1 Capital Advisors LLC holds 7.10M shares, accounting for 7.32% of the total shares.
Soleus Capital Management, L.P. holds 7.05M shares, accounting for 7.28% of the total shares.
OrbiMed Advisors, LLC holds 5.24M shares, accounting for 5.40% of the total shares.
Point72 Asset Management, L.P. holds 8.48M shares, accounting for 8.75% of the total shares.
RA Capital Management, LP holds 8.00M shares, accounting for 8.25% of the total shares.
Lynx1 Capital Advisors LLC holds 7.10M shares, accounting for 7.32% of the total shares.
Soleus Capital Management, L.P. holds 7.05M shares, accounting for 7.28% of the total shares.
OrbiMed Advisors, LLC holds 5.24M shares, accounting for 5.40% of the total shares.
What are the top three shareholder types of C4 Therapeutics Inc?
The top three shareholder types of C4 Therapeutics Inc are:
Point72 Asset Management, L.P.
RA Capital Management, LP
Lynx1 Capital Advisors LLC
Point72 Asset Management, L.P.
RA Capital Management, LP
Lynx1 Capital Advisors LLC
How many institutions hold shares of C4 Therapeutics Inc (CCCC)?
As of 2025Q4, 295 institutions hold shares of C4 Therapeutics Inc, with a combined market value of approximately 70.29M, accounting for 72.52% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -36.30%.
What is the biggest source of revenue for C4 Therapeutics Inc?
In --, the -- business generated the highest revenue for C4 Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
